Literature DB >> 80296

Class-specific antibody titres (ELISA) against the primary immunogen Helix pomatia haemocyanin (HPH) in man.

J Weits, G C de Gast, T H The, M T Esselink, A M Deelder, M Petrovic, E Mandema.   

Abstract

Using the indirect ELISA technique, IgM, IgG and IgA antibody titres against the primary test immunogen Helix pomatia haemocyanin (HPH) could be measured. All twenty-seven normal volunteers (age range 26-74 years) developed maximal or high IgM, IgG and IgA antibody titres 2 weeks after primary immunization with 1.0 mg HPH subcutaneously. Lower dose immunization resulted in submaximal responses. Titre kinetics in the three Ig classes correlated in height and time per person. There was no significant difference in antibody response between two adult age groups. Secondary immunization after 6 weeks, again with 1.0 mg HPH, when high titres were still present, resulted in a small titre increase in all three Ig classes. Comparison with the tanned red cell agglutination technique used previously, in combination with the 2-mercaptoethanol treatment of sera, showed the unreliability of 7S titres measured thus early in the primary immune response. Investigation of four patients with humoral immunodeficiency confirmed the class specificity of the test.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 80296      PMCID: PMC1541332     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

Review 1.  THE HETEROGENEITY OF THE IMMUNE RESPONSE.

Authors:  J W UHR
Journal:  Science       Date:  1964-07-31       Impact factor: 47.728

2.  Schistosoma mansoni: comparison of the immunoperoxidase techniques, DASS and ELISA, for human diagnosis.

Authors:  A M Deelder; E J Ruttenberg; D Kornelis; P A Steerenberg
Journal:  Exp Parasitol       Date:  1977-02       Impact factor: 2.011

3.  The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation.

Authors:  J E Curtis; E M Hersh; J E Harris; C McBride; E J Freireich
Journal:  Clin Exp Immunol       Date:  1970-04       Impact factor: 4.330

4.  Human diphtheria antitoxin in immunoglobulin classes IgG and IgA.

Authors:  R W Newcomb; K Ishizaka
Journal:  J Immunol       Date:  1967-07       Impact factor: 5.422

5.  Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes.

Authors:  E Engvall; P Perlmann
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

6.  The immune response to thetaX 174 in man. I. Primary and secondary antibody production in normal adults.

Authors:  D B Peacock; J V Jones; M Gough
Journal:  Clin Exp Immunol       Date:  1973-04       Impact factor: 4.330

7.  An immunofluorescence procedure for the detection of intracellular immunoglobulins.

Authors:  W Hijmans; H R Schuit; F Klein
Journal:  Clin Exp Immunol       Date:  1969-04       Impact factor: 4.330

8.  The human immune response to alpha-haemocyanin of Helix pomatia.

Authors:  G C de Gast; T H The; J A Snijder
Journal:  Acta Med Scand       Date:  1973-10

9.  Measurement of antibody-producing capacity in man. V. Immunoglobulin classes of antibodies to flagellin.

Authors:  M J Rowley; R Wistar; I R Mackay
Journal:  Immunology       Date:  1972-03       Impact factor: 7.397

10.  Immune response in asymptomatic paraproteinemia. I. Primary and secondary antibody response to Helix pomatia hemocyanin.

Authors:  J Weits; G C de Gast; T H The; J Marrink; E Mandema
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

View more
  9 in total

1.  Increased frequency of B8/DR3 in scleroderma and association of the haplotype with impaired cellular immune response.

Authors:  C G Kallenberg; J M Van der Voort-Beelen; J D'Amaro; T H The
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

2.  Immunoglobulin G and M antibodies to pneumococcal polysaccharides detected by enzyme-linked immunosorbent assay.

Authors:  D J Barrett; A J Ammann; S Stenmark; D W Wara
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

3.  Immune response capacity after human splenic autotransplantation: restoration of response to individual pneumococcal vaccine subtypes.

Authors:  R Leemans; W Manson; J A Snijder; J W Smit; H J Klasen; T H The; W Timens
Journal:  Ann Surg       Date:  1999-02       Impact factor: 12.969

4.  Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.

Authors:  Dominic F Kelly; Matthew D Snape; Kirsten P Perrett; Elizabeth A Clutterbuck; Susan Lewis; Geraldine Blanchard Rohner; Meryl Jones; Ly-Mee Yu; Andrew J Pollard
Journal:  Immunology       Date:  2009-05       Impact factor: 7.397

5.  Antibody responses in vivo in chromosome instability syndromes with immunodeficiency.

Authors:  C M Weemaes; T H The; P J van Munster; J A Bakkeren
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

6.  Passage of ingested protein into the blood during gastrointestinal hypersensitivity reactions: experiments in the preruminant calf.

Authors:  P J Kilshaw; H Slade
Journal:  Clin Exp Immunol       Date:  1980-09       Impact factor: 4.330

7.  B cell activity in systemic lupus erythematosus: depressed in vivo humoral immune response to a primary antigen (haemocyanin) and increased in vitro spontaneous immunoglobulin synthesis.

Authors:  C G Kallenberg; P C Limburg; C Van Slochteren; F J Van der Woude; T H The
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

8.  The primary immune response in patients with selective IgA deficiency.

Authors:  P A De Graeff; T H The; P J van Munster; T A Out; J M Vossen; B J Zegers
Journal:  Clin Exp Immunol       Date:  1983-12       Impact factor: 4.330

9.  Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man.

Authors:  D M C Brinkman; C M Jol-van der Zijde; M M ten Dam; J M Vossen; A D M E Osterhaus; F P Kroon; M J D van Tol
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.542

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.